Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 23 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

14Total
Not Applicable (11)
P 1 (2)
P 2 (1)

Trial Status

Completed8
Recruiting6
Unknown4
Not Yet Recruiting3
Enrolling By Invitation1
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 8 completed trials

Clinical Trials (23)

Showing 20 of 20 trials
NCT07521384Enrolling By Invitation

Real World Outcomes of Intranasal MuSE Exosomes and Stem Cells in Neurological Regenerative Therapy

NCT07202195Not ApplicableRecruiting

At Home Use of Stimulation Suits for Managing MS Symptoms

NCT05991297Not ApplicableCompletedPrimary

Effects of Deep Sensory Assisted Rehabilitation on Gait and Balance in Patients With Multiple Sclerosis

NCT07304960Not Yet RecruitingPrimary

Multiple Sclerosis Versus Neuromyelitis Optica Spectrum Disorder

NCT07235644Active Not RecruitingPrimary

Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple Sclerosis

NCT07222618Recruiting

"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS

NCT07087873Not ApplicableRecruiting

Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases

NCT06999434Phase 1Recruiting

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

NCT06849882RecruitingPrimary

Dubousset Functional Test: an Investigation of Its Validity and Reliability in Individuals with Multiple Sclerosis

NCT06782724Phase 2Not Yet Recruiting

Psilocybin Therapy for Psychological Distress in Palliative Patients

NCT06770959Not Yet RecruitingPrimary

Frequency of Gastrointestinal and Hepatic Manifestations Among Patients with Multiple Sclerosis, a Clinical Hospital Based Study

NCT05857280Not ApplicableRecruiting

EXOPULSE Mollii Suit, Motor Function & Multiple Sclerosis (EXOSEP 2)

NCT05912595Not ApplicableUnknown

EXOPULSE Mollii Suit, Spasticity, Muscular Oxygenation & Multiple Sclerosis (ENNOX 2)

NCT06199219Not ApplicableCompletedPrimary

Ex-Plissit Model Based Counseling on Sexual Function and Sexual Satisfaction

NCT05435404Completed

Qualitative Study Patient & Physician Experiences Botox COVID-19

NCT02490943Not ApplicableCompletedPrimary

A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS

NCT04095377Completed

Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019.

NCT04822623UnknownPrimary

Imaging Evaluation of Central Nervous Autoimmune Diseases

NCT04379661Not ApplicableCompletedPrimary

SUNLIGHT Study: Online Support Groups for MS to Address COVID-19

NCT04530955Not ApplicableUnknown

Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS)

Scroll to load more

Research Network

Activity Timeline